謝方云

謝方云
教授 主任醫(yī)師，愽士生導(dǎo)師。
擅長頭頸部腫瘤放射治療，特別是鼻咽癌的精確調(diào)強(qiáng)放療和綜合治療。曾主持和參與國家自然科學(xué)基金重點(diǎn)項(xiàng)目、國家自然科學(xué)基金面上項(xiàng)目,衛(wèi)生部臨床學(xué)科重點(diǎn)項(xiàng)目,廣東省科技計(jì)劃項(xiàng)目多個(gè)，參與項(xiàng)目的研究成果榮獲2014年廣東省科學(xué)技術(shù)一等獎(jiǎng)、中華醫(yī)學(xué)科技一等獎(jiǎng)及國家科技進(jìn)步二等獎(jiǎng)。擔(dān)任Br J Cancer,Cancer Epidemiol Biomarkers Pre,Tumor Biol,Radiat Oncol,Oral Oncol 等,雜志審稿人。主要研究鼻咽癌綜合治療方案、腫瘤分期及預(yù)后因素，近年以第一作者或通訊作者在Ann Oncol,Br J Cancer,J Biol Chem,Lancet Oncol,NEJM 等腫瘤學(xué)期刊發(fā)表論文30余篇，其臨床研究成果得到美國癌癥研究協(xié)會(huì)（AACR）網(wǎng)站新聞報(bào)道。

主要科研項(xiàng)目：
　　1)中山大學(xué)臨床醫(yī)學(xué)研究5010計(jì)劃項(xiàng)目，調(diào)強(qiáng)放療加或不加同期化療治療低危鼻咽癌的III期非劣效性、隨機(jī)對(duì)照、多中心研究，經(jīng)費(fèi)200萬，2015-2025，第一負(fù)責(zé)人；
　　2)國家自然科學(xué)基金重點(diǎn)項(xiàng)目，cdh1(FZR1)磷酸化新點(diǎn)被調(diào)控的機(jī)理，對(duì)功能的影響及其 意義，經(jīng)費(fèi)174萬，2009-2013，第二負(fù)責(zé)人；
　　3)中山大學(xué)臨床醫(yī)學(xué)研究5010計(jì)劃，局部區(qū)域晚期鼻咽癌吉西他濱及順鉑誘導(dǎo)化療聯(lián)合同期放化療對(duì)比同期放化療的前瞻性多中心III期臨床研究，經(jīng)費(fèi)200萬， 2014-2023，第三負(fù)責(zé)人；
　　4)衛(wèi)生部臨床學(xué)科重點(diǎn)項(xiàng)目，基于調(diào)強(qiáng)放射療的鼻咽癌預(yù)后模型及TPF誘導(dǎo)化療的前瞻性研究，經(jīng)費(fèi)200萬，2010-2013，第三負(fù)責(zé)人；
5）國家自然科學(xué)基金委員會(huì)，F(xiàn)li-1靶向上調(diào)VEGF-C促進(jìn)鼻咽癌轉(zhuǎn)移的分子機(jī)制和臨床意義研究，經(jīng)費(fèi)52萬，2017-2020，第一負(fù)責(zé)人；
6）廣東省自然科學(xué)基金管理委員會(huì)，F(xiàn)li-1靶向調(diào)控VEGF-C促進(jìn)鼻咽癌生長和轉(zhuǎn)移的研究，經(jīng)費(fèi)10萬，2017-2020，第一負(fù)責(zé)人；
7）廣東省科學(xué)技術(shù)廳，多西他賽加順鉑（TP）對(duì)比單藥順鉑（DDP）的同期化療聯(lián)合調(diào)強(qiáng)放療治療高危局部區(qū)域晚期鼻咽癌的隨機(jī)對(duì)照II期臨床研究；經(jīng)費(fèi)10萬，2016-2018，第一負(fù)責(zé)人。

獲獎(jiǎng): 參與研究項(xiàng)目獲2014年廣東省科學(xué)技術(shù)一等獎(jiǎng)、中華醫(yī)學(xué)科技一等獎(jiǎng)及國家科技進(jìn)步二等獎(jiǎng)。

第一作者及通訊作者論文

第一及或通訊作者發(fā)表SCI文章
1. Xiang-Bo Wan, Rou Jiang, Fang-Yun Xie (Co-first authors), Zhen-Yu Qi, Ai-Ju Li, Wei-Jun Ye, Yi-Jun Hua, Yu-Liang Zhu, Xiong Zou, Ling Gao, Hai-Qiang Mai, Xiang Guo, Ming-Huang Hong, Ming Yuan Che. Endoscope—guided interstitial intensity-modulated brachytherapy and intracavitary brachytherapy as boost radiation for primary early T stage nasopharyngeal carcinoma. PLoS One 2014;9;e90048.(IF 2.806)
2. Xiao-Bin Lv, Fangyun Xie (Co-first authors), Kaishun Hu, Yuanzhong Wu, Lin-Lin Cao, Xia Han, Yi Sang, Yi-Xin Zeng, and Tiebang Kang. Damaged DNA-binding protein 1(DDB1) interacts with Cdhl and modulates the function of APC/CCdhl. J Biol Chem 2010; 285:18234-18240.（IF 4.125）
3. Pu-Yun OuYang, MD, Lu-Ning Zhang, MD, Jie Tang, MD, Xiao-Wen Lan, MD, Yao Xiao, MD, Yuan-Hong Gao, MD, and Fang-Yun Xie, Md. Evaluation of Body Mass Index and Survival of Nasopharyngeal Carcinoma by Propensity-Matched Analysis: An Observational Case-Control Study. Medicine (Baltimore)2016;95:e2380(IF 1.803)
4. Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Zhen Su, Jun Ma, Wuguo Deng,Pu-Yun OuYang, Fang-Yun Xie. Propensity score matching analysis of cisplatin-based concurrent chemotheraoy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotheraphy era. Oncotarget 2015;6:44019-44029(IF 5.168)
5. P-Y OuYang, L-N Zhang, X-W Lan, C Xie, W-W Zhang, Q-X Wang, Z Su, J Tang and F-Y Xie. The significant survival advantage of female sex in nasopharyngeal carcinoma:a propensity-matched analysis. Br J Cancer 2015;112:1554-1561(IF 6.176)
6. Lu-Ning Zhang, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie. Pretreatment anemia and survival in nasopharyngeal carcinoma. Tumour Biol 2015(IF 3.65)
7. Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun Ouyang, Fang-Yun Xie. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT:a retrospective study. Tumour Biol 2015(IF 3.65)
8. Lu-Ning Zhang, Yuan-Hong Gao, Xiao-Wen Lan, Jie Tang, Pu-Yun OuYang, Fang-Yun Xie. Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A large scale propensity-matched study. Oral Oncol 2015;51:950-956(IF 4.794)
9. Zhen Su, Yan-Ping Mao, Pu-Yun OuYang, Jie Tang, Xiao-Wen Lan and Fang-Yun Xie. Leucopenia and treatment efficacy in advanced nasopharyngeal carcinoma. BMC Cancer 2015;15:429(IF 3.288)
10. Zhen Su, Yan-Ping Mao, Pu-Yun OuYang, Jie Tang, Fang-Yun Xie. Initial Hyperleukocytosis and Neutrophilia in Nasopharyngeal Carcinoma: Incidence and Prognostic Impact. PLoS One2015;10:e0136752（IF 2.806）
11. Xue-Xia Liang, Qun Li, Zhen Su, Xiao-Wen Lan, Pu-Yun OuYang, Yan-Ping Mao, Ding-Bo Shi, Wu-Guo Deng, Zhi-Bin Cheng, Si-Yang Wang, Fang-Yun Xie. Significant prognostic impact of chemoradiatherapy-induced hemoglobin decrease on treatment outcomes of nasopharyngeal carcinoma. J Cancer 2015;6;:502-510(IF 2.916)
12. Pu-Yun OuYang, Zhen Su, Jie Tang, Xiao-Wen Lan, Yan-Ping Mao,Wuguo Deng, Fang-Yun Xie. Diabetes,Prediabetes and the Survival of Nasopharyngeal Carcinoma:A Study of 5,860 Patients. PLoS One2014;9:e111073(IF 2.806)
13. Xuexia Liang, Dingbo Shi, Jingping Yun, Yanping Mao,Puyun Ouyang, Zhen Su, Jia Fu, Jinghui Hou, Wuguo Deng and Fangyun Xie. Friend leukemia virus integration 1 expression has prognostic significance in nasopharyngeal carcinoma. Transl Oncol 2014;7:493-502(IF 3.025)
14.P.Y.OuYang,C.Xie,Y.P.Mao,Y.Zhang,X.X.Liang,Z.Su,Q.Liu&F.Y.Xie. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol 2013;24:2136-2146(IF 11.855)
15. P-Y OuYang, Z Su, Y-P Mao, Q Liu and F-Y Xie. Prognostic value of ABO blood group in southern Chinese patients with established nasopharyngeal carcinoma. Br J Cancer 2013;109:2462-2466(IF 6.176)
16. Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Xue-Xia Liang, Qing Liu, Wu-Guo Deng, and Fang-Yun Xie. Prognostic impact of family history in southern Chinese patients with undifferentiated nasopharyngeal carcinoma. Br J Cancer 2013;109:788-794(IF 6.176)
17. P-Y OuYang, Z Su,X-H Ma, Y-P Mao, M-Z Liu and F-Y Xie. Comparison of TNM staging systems for nasopharyngeal carcinoma, and proposal of a new staging system. Br J Cancer 2013;109:2987-29979（IF 6.176）
18. P-Y OuYang, Z Su, Y-P Mao, X-X Liang, Q Liu and F-Y Xie. Prognostic impact of cigarette smoking on the survival of patients with established nasopharyngeal carcinoma.Cancer Epidemiol Biomarkers Prev 2013;22:2285-2294(IF 6.176)
19. Pu-Yun OuYang, Zhen Su, Yan-Ping Mao, Wuguo Deng, Fang-Yun Xie. Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC:A Meta-Analysis. PLoS One2018;8:e79000(IF 2.806)
20. Xin Wang, Yi Liang, Qiong Chen, Hui-Min Xu, Nan Ge,Rong-Zhen Luo, Jian-Yong Shao, Zhi-Wei He, Yi-Xin Zeng, Tiebang Kang, Jing-Ping Yun &Fangyun Xie. Prognostic significance of SOX2 exoression in nasopharyngeal carcinoma. Cancer Invest 2012;30:79-85(IF 2.007)
21. Hui-Min Xu, Yi Liang, Qiong Chen, Qi-Nian Wu, Yun-Miao Guo, Guo-Ping Shen, Ru-Hua Zhang, Zhi-Wei He, Yi-Xin Zeng, Fang-Yun Xie, and Tie-Bang Kang. Correlation of Skp2 overexpression to prognosis of patients with nasopharyngeal carcinoma from South China. Chin J Cancer2011;30:204-212(IF 4.111)
22. Pu-Yun OuYang, Dingbo Shi, Rui Sun, Yu-Jia Zhu, Yao Xiao,Lu-Ning Zhang, Xu-Hui Zhang, Ze-Ying Chen, Xiao-Wen Lan, Jie Tang, Yuan-Hong Gao, Jun Ma, Wuguo Deng, Fang-Yun Xie. Effect of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy alone in nasopharyngeal carcinoma. Oncotarget. 2016 Apr 4.(IF 5.168)
23. Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study. Tumor Biol. 2016 Apr;37(4):4429-38(IF 3.65)
24. Pu-Yun OuYang, Zhuo-Fei Bi, Lu-Ning Zhang, Kai-Yun You, Yao Xiao, Xiao-Wen Lan, Jie Tang, Xi-Cheng Wang, Wuguo Deng and Fang-Yun Xie. Outcomes of Induction Chemotherapy Plus Intensity-Modulated Radiotherapy (IMRT) Versus IMRT Plus Concurrent Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Study. Transl Oncol. 2016; 9(4):329-335.(IF 3.025)
25. Xiao-Wen Lan, Xue-Bin Zou, Yao Xiao, Jie Tang, Pu-Yun OuYang, Zhen Su, Fang-Yun Xie. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage Iva-b Nasopharyngeal Carcinoma:Plos One.2016;11(8):e0160758.(IF 2.806)
26. Lei Chen, Chao-Su Hu, Xiao-Zhong Chen, Guo-Qing Hu, Zhi-Bin Cheng, Yan Sun, Wei-Xiong Li, Yuan-Yuan Chen, Fang-Yun Xie, Shao-Bo Liang, Yong Chen, Ting-Ting Xu, Bin Li, Guo-Xian Long, Si-Yang Wang, Bao-Min Zheng, Ying Guo, Ying Sun, Yan-Ping Mao, Ling-Long Tang, Yu-Ming Chen, Meng-Zhong Liu, Jun Ma.Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomiased controlled trial. Lancet Oncol2012;13:163-71(IF 33.9)
27. Ying Sun, Wen-Fei Li, Nian-Yong Chen, Ning Zhang, Guo-Qing Hu, Fang-Yun Xie (Co-first authors), Yan Sun, Xiao-Zhong Chen, Jin-Gao Li, Xiao-Dong Zhu. Chao-Su Hu, Xiang-Ying Xu, Yuan-Yuan Chen, Wei-Han Hu, Ling Guo, Hao-Yuan Mo, Lei Chen, Yan-Ping Mao, Rui-Sun, Ping Ai, Shao-Bo Liang, Guo-Xian Long, Bao-Min Zhang, Xing-Lai Feng, Xiao-Chang Gong, Ling Li, Chun-Ying Shen, Jian-Yu Xu, Ying Guo, Yu-Ming Chen, Dan Zhang, Li Lin, Ling-Long Tang, Meng-Zhong Liu, Jun Ma. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicenter, randomized controlled trial. Lancet Oncol 2016:1470-2045(IF 33.9)
28. Xiao-Wen Lan, Yao Xiao, Xue-Bin Zou, Pu-Yun OuYang, Fang-Yun Xie. Outcomes of adding induction chemotherapy to concurrent chemoradiotherapy for stage T3N0-1 nasopharyngeal carcinoma: a propensity-matched study. OncoTargets and Therapy 2017:10 3853-3860(IF 2.3184)
29. Pu-Yun OuYang, Yao Xiao, Kai-Yun You, Lu-Ning Zhang, Xiao-Wen Lan, Xiao-Min Zhang, Fang-Yun Xie. Validation and comparison of the 7th and 8th edition of AJCC staging systems for non-metastatic nasopharyngeal carcinoma, and proposed staging systems from Hong Kong, Guangzhou, and Guangxi. Oral Oncol 2017; 72: 65-72. (IF 4.794)
30. Pu-Yun OuYang, Lu-Ning Zhang, Yao Xiao, Xiao-Wen Lan, Xiao-Min Zhang, Jun Ma, Fang-Yun Xie. Validation of published nomograms and accordingly individualized induction chemotherapy in nasopharyngeal carcinoma. Oral Oncol 2017;67:37-45.(IF 4.794)